Literature DB >> 21990946

Betaine and nonalcoholic steatohepatitis: back to the future?

Sandeep Mukherjee.   

Abstract

Nonalcoholic steatohepatitis (NASH) is an important indication for liver transplantation in many Western countries. Obesity and insulin resistance are the two most common risk factors for NASH, which can lead to recurrent NASH after liver transplantation. There is currently no approved therapy for NASH, and treatment is directed at risk factor modification and lifestyle changes. Betaine has been used for NASH, with mixed results, and may show promise in conjunction with other agents in clinical trials.

Entities:  

Keywords:  Betaine; Cirrhosis; Insulin resistance; Nonalcoholic steatohepatitis; Obesity

Mesh：

Substances：

Year:  2011        PMID： 21990946      PMCID： PMC3181450          DOI： 10.3748/wjg.v17.i32.3663

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  10 in total

1.  Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine.

Authors:  Elango Kathirvel; Kengathevy Morgan; Ganesh Nandgiri; Brian C Sandoval; Marie A Caudill; Teodoro Bottiglieri; Samuel W French; Timothy R Morgan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-08-19       Impact factor: 4.052

2.  Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study.

Authors:  F Miglio; L C Rovati; A Santoro; I Setnikar
Journal:  Arzneimittelforschung       Date:  2000-08

3.  Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease.

Authors:  M Charlton; P Kasparova; S Weston; K Lindor; Y Maor-Kendler; R H Wiesner; C B Rosen; K P Batts
Journal:  Liver Transpl       Date:  2001-07       Impact factor: 5.799

4.  Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study.

Authors:  M F Abdelmalek; P Angulo; R A Jorgensen; P B Sylvestre; K D Lindor
Journal:  Am J Gastroenterol       Date:  2001-09       Impact factor: 10.864

5.  Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease.

Authors:  Kausik Das; Kshaunish Das; Partha S Mukherjee; Alip Ghosh; Sumantra Ghosh; Asit R Mridha; Tapan Dhibar; Bhaskar Bhattacharya; Dilip Bhattacharya; Byomkesh Manna; Gopal K Dhali; Amal Santra; Abhijit Chowdhury
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

Review 6.  The natural history of non-alcoholic fatty liver disease.

Authors:  Stephen Caldwell; Curtis Argo
Journal:  Dig Dis       Date:  2010-05-07       Impact factor: 2.404

7.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

Review 8.  Betaine in human nutrition.

Authors:  Stuart A S Craig
Journal:  Am J Clin Nutr       Date:  2004-09       Impact factor: 7.045

9.  Serum betaine, N,N-dimethylglycine and N-methylglycine levels in patients with cobalamin and folate deficiency and related inborn errors of metabolism.

Authors:  R H Allen; S P Stabler; J Lindenbaum
Journal:  Metabolism       Date:  1993-11       Impact factor: 8.694

10.  Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial.

Authors:  Manal F Abdelmalek; Schuyler O Sanderson; Paul Angulo; Consuelo Soldevila-Pico; Chen Liu; Joy Peter; Jill Keach; Matt Cave; Theresa Chen; Craig J McClain; Keith D Lindor
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425
  10 in total
  5 in total

Review 1.  Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.

Authors:  Alessandro Federico; Claudio Zulli; Ilario de Sio; Anna Del Prete; Marcello Dallio; Mario Masarone; Carmela Loguercio
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

2.  Herbal products: benefits, limits, and applications in chronic liver disease.

Authors:  Anna Del Prete; Antonella Scalera; Maddalena Diana Iadevaia; Agnese Miranda; Claudio Zulli; Laura Gaeta; Concetta Tuccillo; Alessandro Federico; Carmelina Loguercio
Journal:  Evid Based Complement Alternat Med       Date:  2012-09-06       Impact factor: 2.629

3.  Changes in human hepatic metabolism in steatosis and cirrhosis.

Authors:  Zoe Schofield; Michelle Ac Reed; Philip N Newsome; David H Adams; Ulrich L Günther; Patricia F Lalor
Journal:  World J Gastroenterol       Date:  2017-04-21       Impact factor: 5.742

Review 4.  Regulation of Cytochrome c Oxidase by Natural Compounds Resveratrol, (-)-Epicatechin, and Betaine.

Authors:  Icksoo Lee
Journal:  Cells       Date:  2021-05-29       Impact factor: 6.600

Review 5.  Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD).

Authors:  Madhangi Parameswaran; Hamzah A Hasan; Jafor Sadeque; Sharan Jhaveri; Chaithanya Avanthika; Abimbola E Arisoyin; Maulik B Dhanani; Swaroopa M Rath
Journal:  Cureus       Date:  2021-12-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.